Prof Andrew Wilson announced as new Chair for Pharmaceutical Benefits Advisory Committee (PBAC)

… the Pharmaceutical Benefits Advisory Committee (PBAC), the independent expert body whose primary role is to recommend new medicines for listing on the Pharmaceutical Benefits Scheme (PBS). In a statement, the Minister also announced that new …

See more here:
Prof Andrew Wilson announced as new Chair for Pharmaceutical Benefits Advisory Committee (PBAC)

Responding to parts 2-3 of New England Journal of Medicine’s series on pharma-MD relations

Dr. Susan Molchan responds to the second and third pieces of a series by New England Journal of Medicine national correspondent Dr

Visit link:
Responding to parts 2-3 of New England Journal of Medicine’s series on pharma-MD relations

Canada Lags Far Behind Other Countries In New Medicines

If you want cheap medicine, Canadian taxpayers make it possible to get a great deal, but when it comes to new medicines, Canada is behind similar countries, according to a new report which ranks it 16th out of 18 comparable OECD countries. Only 23% of 141 …

View original post here:
Canada Lags Far Behind Other Countries In New Medicines

Canada lags behind its peers in new medicine access

In 2014, only a quarter of the 141 new medicines approved by Health Canada were included in public drug plans, ranking Canada 17 out of 18 on this front. These are the findings of a new IMS Brogan report commissioned by Rx&D.

See the article here:
Canada lags behind its peers in new medicine access

Canadians lagging well behind similar countries on access to new medicines: report

OTTAWA, May 21, 2015 /CNW/ - Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in public drug plans, according to a new IMS Brogan report commissioned by Rx&D. Overall, the report ranks Canada 16 …

Read more:
Canadians lagging well behind similar countries on access to new medicines: report

J&J to seek regulatory approval for 10 new drugs by 2019 that may generate over $1 bln revenue

Shares of J&N fell 0.3 percent to 103.69 at 2:59 p.m. in New York.

Read this article:
J&J to seek regulatory approval for 10 new drugs by 2019 that may generate over $1 bln revenue

J&J to submit at least 10 new drugs for approval by 2019

U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

Read the original here:
J&J to submit at least 10 new drugs for approval by 2019

Johnson & Johnson Plans for 10 New Drugs — Is It Time to Own the Stock?

Must Read: Warren Buffett’s Top 10 Dividend Stocks The company also announced more than 40 line extensions of existing and new medicines. “Our innovation strategy has delivered transformational products for patients and also created a cycle of success that …

See the original post:
Johnson & Johnson Plans for 10 New Drugs — Is It Time to Own the Stock?

J&J says will submit 10 medicines to regulators by 2019

NEW YORK (Reuters) - Drugmaker Johnson & Johnson said on Wednesday that it would submit 10 new medicines to regulators by 2019, forecasting that many of the drugs in its research and development pipeline will have more than $1 billion in peak annual sales.

Continued here:
J&J says will submit 10 medicines to regulators by 2019

J&J to submit at least 10 medicines for approval by 2019

U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

Here is the original post:
J&J to submit at least 10 medicines for approval by 2019